Global pharmaceutical giant Eli Lilly and Company has announced plans to invest over USD 1 billion in India to expand its manufacturing capabilities and strengthen its presence in one of the world’s fastest-growing healthcare markets.
The investment will focus on establishing new production facilities and enhancing existing infrastructure to support the company’s portfolio of innovative medicines, including treatments for diabetes, oncology, and immunology. The move underscores India’s growing role as a critical hub for pharmaceutical manufacturing and research.
According to a report by Reuters, the expansion is part of Eli Lilly’s broader global strategy to diversify its supply chain and meet increasing demand for its key therapeutic products. The company aims to create hundreds of skilled jobs in the process, contributing significantly to India’s biotechnology and healthcare ecosystem.
Speaking about the investment, Eli Lilly CEO David A. Ricks emphasized that India offers both manufacturing excellence and scientific talent, making it an ideal location for long-term growth. “Our commitment reflects the potential we see in India as a partner in our mission to make life better for people around the world,” Ricks said.
Industry experts believe this move could encourage more multinational drugmakers to deepen their roots in India, where government initiatives are actively promoting pharmaceutical innovation and local production.
